Literature DB >> 18401866

Release of prostaglandin E(1) from N-(2-hydroxypropyl)methacrylamide copolymer conjugates by bone cells.

Huaizhong Pan1, Jihua Liu, Yuanyi Dong, Monika Sima, Pavla Kopecková, Maria Luisa Brandi, Jindrich Kopecek.   

Abstract

Bone-targeting N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-PGE(1) conjugates, containing cathepsin K sensitive spacers, were incubated with induced osteoclasts and osteoblasts, their precursors, and control non-skeletal cells. The release of PGE(1) was monitored by an HPLC assay. In both murine and human cell lines, osteoclasts appeared to be the most active cells in the cleavage (PGE(1) release). Incubation with osteoblasts also resulted in fast PGE(1) release, whereas precursor and control cells released PGE(1) with a substantially slower rate than bone cells (apparently through ester bond cleavage). Experiments in the presence of inhibitors revealed that other enzymes, in addition to cathepsin K, were participating in the cleavage of the conjugate. Confocal fluorescence studies exposed internalization of the conjugate by endocytosis with ultimate localization in the lysosomal/endosomal compartment.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18401866      PMCID: PMC4605216          DOI: 10.1002/mabi.200700338

Source DB:  PubMed          Journal:  Macromol Biosci        ISSN: 1616-5187            Impact factor:   4.979


  33 in total

1.  Human osteoclast cathepsin K is processed intracellularly prior to attachment and bone resorption.

Authors:  R A Dodds; I E James; D Rieman; R Ahern; S M Hwang; J R Connor; S D Thompson; D F Veber; F H Drake; S Holmes; M W Lark; M Gowen
Journal:  J Bone Miner Res       Date:  2001-03       Impact factor: 6.741

2.  RANKL-mediated osteoclast formation from murine RAW 264.7 cells.

Authors:  Patricia Collin-Osdoby; Xuefeng Yu; Hong Zheng; Philip Osdoby
Journal:  Methods Mol Med       Date:  2003

Review 3.  Meta-analyses of therapies for postmenopausal osteoporosis. I. Systematic reviews of randomized trials in osteoporosis: introduction and methodology.

Authors:  Ann Cranney; Peter Tugwell; George Wells; Gordon Guyatt
Journal:  Endocr Rev       Date:  2002-08       Impact factor: 19.871

4.  Characterization of a human osteosarcoma cell line (Saos-2) with osteoblastic properties.

Authors:  S B Rodan; Y Imai; M A Thiede; G Wesolowski; D Thompson; Z Bar-Shavit; S Shull; K Mann; G A Rodan
Journal:  Cancer Res       Date:  1987-09-15       Impact factor: 12.701

5.  Human cathepsin K cleaves native type I and II collagens at the N-terminal end of the triple helix.

Authors:  W Kafienah; D Brömme; D J Buttle; L J Croucher; A P Hollander
Journal:  Biochem J       Date:  1998-05-01       Impact factor: 3.857

6.  Pharmacokinetic and biodistribution studies of a bone-targeting drug delivery system based on N-(2-hydroxypropyl)methacrylamide copolymers.

Authors:  Dong Wang; Monika Sima; R Lee Mosley; Jasmine P Davda; Nicole Tietze; Scott C Miller; Peter R Gwilt; Pavla Kopecková; Jindrich Kopecek
Journal:  Mol Pharm       Date:  2006 Nov-Dec       Impact factor: 4.939

7.  Prostaglandin E2 enhances cortical bone mass and activates intracortical bone remodeling in intact and ovariectomized female rats.

Authors:  W S Jee; S Mori; X J Li; S Chan
Journal:  Bone       Date:  1990       Impact factor: 4.398

Review 8.  Bone resorption by osteoclasts.

Authors:  S L Teitelbaum
Journal:  Science       Date:  2000-09-01       Impact factor: 47.728

9.  Targetable HPMA copolymer-adriamycin conjugates. Recognition, internalization, and subcellular fate.

Authors:  V Omelyanenko; P Kopecková; C Gentry; J Kopecek
Journal:  J Control Release       Date:  1998-04-30       Impact factor: 9.776

10.  Characterization of lysosomal acid lipase by site-directed mutagenesis and heterologous expression.

Authors:  S Sheriff; H Du; G A Grabowski
Journal:  J Biol Chem       Date:  1995-11-17       Impact factor: 5.157

View more
  7 in total

Review 1.  Targeting polymer therapeutics to bone.

Authors:  Stewart A Low; Jindřich Kopeček
Journal:  Adv Drug Deliv Rev       Date:  2012-01-28       Impact factor: 15.470

Review 2.  Beyond oncology--application of HPMA copolymers in non-cancerous diseases.

Authors:  Xin-Ming Liu; Scott C Miller; Dong Wang
Journal:  Adv Drug Deliv Rev       Date:  2009-11-10       Impact factor: 15.470

Review 3.  Polymer-drug conjugates: origins, progress to date and future directions.

Authors:  Jindřich Kopeček
Journal:  Adv Drug Deliv Rev       Date:  2012-11-02       Impact factor: 15.470

4.  Efficiency of high molecular weight backbone degradable HPMA copolymer-prostaglandin E1 conjugate in promotion of bone formation in ovariectomized rats.

Authors:  Huaizhong Pan; Monika Sima; Scott C Miller; Pavla Kopečková; Jiyuan Yang; Jindřich Kopeček
Journal:  Biomaterials       Date:  2013-06-02       Impact factor: 12.479

5.  HPMA copolymers: origins, early developments, present, and future.

Authors:  Jindrich Kopecek; Pavla Kopecková
Journal:  Adv Drug Deliv Rev       Date:  2009-11-14       Impact factor: 15.470

6.  Protease-activated drug development.

Authors:  Ki Young Choi; Magdalena Swierczewska; Seulki Lee; Xiaoyuan Chen
Journal:  Theranostics       Date:  2012-02-08       Impact factor: 11.556

Review 7.  Bisphosphonate conjugation for bone specific drug targeting.

Authors:  Kristen B Farrell; Alexander Karpeisky; Douglas H Thamm; Shawn Zinnen
Journal:  Bone Rep       Date:  2018-07-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.